For the treatment of diseases in which dysregulation of necroptosis occurs, such as neurodegenerative diseases, sepsis, and cancer, RIPK1 serine 331 O-GlcNAcylation warrants further study as a useful therapeutic target or strategy. This evidence concerns the gene RIPK1 and cancer.